From Wikipedia, the free encyclopedia
Jump to: navigation, search
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target IL-5
Clinical data
Trade names Nucala
AHFS/ nucala
Pharmacokinetic data
Biological half-life 20 days
CAS Number 196078-29-2 N
ATC code L04AC06 (WHO)
PubChem SID 47206675
DrugBank DB06612 YesY
ChemSpider none
KEGG D04923 YesY
 NYesY (what is this?)  (verify)

Mepolizumab (trade name Nucala) is a humanized monoclonal antibody that recognizes interleukin-5 (IL-5). Mepolizumab has been investigated or is under investigation for the treatment of severe eosinophilic asthma, atopic dermatitis, hypereosinophilic syndrome (HES), eosinophilic esophagitis (EoE), nasal polyposis, eosinophilic granulomatosis with polyangiitis (EGPA) and chronic obstructive pulmonary disease (COPD). Phase III clinical trials in severe eosinophilic asthma were completed in 2014.

Mepolizumab is approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of severe asthma in patients aged 12 years or older and with an eosinophilic phenotype in combination with other medicines used to treat asthma.[1]

The European Commission granted a marketing authorisation valid throughout the European Union on 2 December 2015. In Europe Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients. [2]


  1. ^ "FDA approves Nucala to treat severe asthma". FDA. 
  2. ^ "Summary for the public" (PDF). European Medicines Agency.